Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Actiphage TB test patent extended to West Africa

PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.
  • February 24, 2023
  • Latest, Press release

Actiphage is a unique diagnostic for early-stage infection. It can identify live cells of Mycobacteria tuberculosis (M.tb) from a blood sample, providing evidence that a person is carrying an active infection that will progress to full disease unless treated (incipient TBI).

Improved diagnostics for identifying people with incipient TBI, before they show clinical symptoms of the disease, is a strategic priority in the WHO #EndTB strategy. PBD Biotech holds two patent portfolios in this area: 2015 ‘Mycobacteria detection using bacteriophages’, and 2020 ‘Methods relating to Tuberculosis’, which specifically covers its tests for incipient TB.

Jane Theaker, Chief Executive of PBD Biotech, says: “Actiphage offers a potential game-changer in the detection and treatment of people with incipient TB. By identifying those with active disease before they start to transmit the bacteria, it offers potential to break the cycle of infection.

“We are currently working in Zambia and South Africa on clinical studies. We are pleased to report on the grant of this patent as it provides evidence of our commitment to expand our operations and patent portfolio, while protecting our interests in this competitive market.”

The patent is supported by a study published in Clinical Infectious Diseases: ‘A Novel, High-sensitivity, Bacteriophage-based Assay Identifies Low-level Mycobacterium Tuberculosis Bacteraemia in Immunocompetent Patients with Active and Incipient Tuberculosis’ (DOI: 10.1093/cid/ciz548). The study was led by Raman Verma and Pranabashis Haldar of the National Institute for Health Research Respiratory Biomedical Research Centre at University of Leicester.

Using a novel, phage-based blood assay, the researchers reported the first concordant evidence to demonstrate associations of Mtb bacteraemia with progressive phenotypes of latent infection and active pulmonary tuberculosis (PTB). The researchers concluded that Actiphage offers promise as a blood-based diagnostic tool for infectious PTB to allow for earlier diagnoses in patients unable to expectorate sputum.

The study was in a well-characterized, immunocompetent human cohort and offered a sensitivity of 73% and specificity of 100% in symptomatic patients with suspected PTB. For all patients, Actiphage had a specificity of 94% with no change in sensitivity.

Actiphage was identified by the recent TAG Pipeline Report as the only test in development able to detect bacteraemia. It offers clear advantages as a rapid, low-cost assay that offers a microbiological diagnosis in the absence of sputum.

Share:

Related posts

Loading...
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic...
AACC webinar phage-based TB diagnostics

19 April 2023

‘We can #EndTB’ – phage-based diagnostics for TB to be discussed at AACC webinar

March 22, 2023
The role of phage-based laboratory diagnostics in the detection of tuberculosis is to be discussed in a live webinar hosted by the AACC, it has been announced ahead of World TB Day.
AACC webinar phage-based TB diagnostics

19 April 2023

‘We can #EndTB’ – phage-based diagnostics for TB to be discussed at AACC webinar

March 22, 2023
The role of phage-based laboratory diagnostics in the detection of tuberculosis is to be discussed in a live webinar hosted...
PCR bead

Novel PCR reaction bead extends global reach of active TB test by removing the cold chain

March 17, 2023
Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB. This enables ambient shipping without the need for a cold...
PCR bead

Novel PCR reaction bead extends global reach of active TB test by removing the cold chain

March 17, 2023
Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
1 2 … 7 Next »

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!